The Nottingham Research Programme in breast cancer.
D000047:Academies and Institutes; D000911:Antibodies, Monoclonal / Q000032:analysis; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000556:secondary / Q000628:therapy; D015232:Dinoprostone; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008408:Mastectomy; D009367:Neoplasm Staging; D011230:Precancerous Conditions / Q000175:diagnosis; D011379:Prognosis; D011458:Prostaglandins E / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D012106:Research; D006113:United Kingdom
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D011458:Prostaglandins E; D011960:Receptors, Estrogen; D015232:Dinoprostone